June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Visual and Anatomic Outcomes in nAMD Patients with Subretinal Hemorrhage After Treatment with Faricimab in the TRUCKEE Study
Hannah Khan; Aamir Abdul Aziz; Ashkan Michael Abbey; David RP Almeida; Robert L Avery; Himanshu K Banda; Mark Barakat; Ramanath Bhandari; Emmanuel Y Chang; Sara Haug; Nikolas J S London; Veeral Sheth; Jeremy Wolfe; Michael Andrew Singer; Carl J Danzig; Arshad M. Khanani
Author Affiliations & Notes
  • Hannah Khan
    University of Nevada Reno School of Medicine, Reno, Nevada, United States
  • Aamir Abdul Aziz
    University of Nevada Reno School of Medicine, Reno, Nevada, United States
  • Ashkan Michael Abbey
    Texas Retina Associates, Dallas, Texas, United States
  • David RP Almeida
    Erie Retinal Surgery Inc, Erie, Pennsylvania, United States
  • Robert L Avery
    California Retina Consultants, Santa Barbara, California, United States
  • Himanshu K Banda
    Sound Retina, Tacoma, Washington, United States
  • Mark Barakat
    Retinal Consultants of Arizona, Phoenix, Arizona, United States
  • Ramanath Bhandari
    Springfield Clinic Eye Institute, Springfield, Illinois, United States
  • Emmanuel Y Chang
    Retina and Vitreous of Texas, Houston, Texas, United States
  • Sara Haug
    Southwest Eye Consultants, Durango, Colorado, United States
  • Nikolas J S London
    Retina Consultants San Diego, Poway, California, United States
  • Veeral Sheth
    University Retina, Chicago, Illinois, United States
  • Jeremy Wolfe
    Associated Retinal Consultants, Royal Oak, Michigan, United States
  • Michael Andrew Singer
    Medical Center Ophthalmology Associates, San Antonio, Texas, United States
  • Carl J Danzig
    Rand Eye Institute, Deerfield Beach, Florida, United States
  • Arshad M. Khanani
    University of Nevada Reno School of Medicine, Reno, Nevada, United States
    Sierra Eye Associates, Reno, Nevada, United States
  • Footnotes
    Commercial Relationships   Hannah Khan None; Aamir Aziz Gemini Therapeutics, Code C (Consultant/Contractor), REGENEXBIO, Code E (Employment); Ashkan Abbey Genentech, Code C (Consultant/Contractor); David Almeida Acelyrin, Alcon, Alimera Sciences, Allergan, Abbvie, Bausuch & Lomb, Bayer, Boehringer Ingelheim, Citrus Therapeutics, Clinical Trials Network, Eyepoint Pharmaceuticals, Genentech, Gyroscope Therapeutics, Novartis, Ocugen, Opthea, Regeneron, REGENXBIO, Roche, Samsara Vision, Spherix Consulting Group, Code C (Consultant/Contractor), Acelyrin, Alimera Sciences, Allergan, Abbvie, Boehringer Ingelheim, Clinical Trials Network, Eyepoint Pharmaceuticals, Genentech, Gyroscope Therapeutics, Novartis, Opthea, REGENXBIO, Roche, Samsara Vision, Code F (Financial Support), Citrus Therapeutics, Code O (Owner); Robert Avery Alcon, Alimera, Amgen, Asclepix, Aviceda, Bausch & Lomb, Clearside, Eyepoint, Genentech, Glaukos, Imprimis, Ingenia, Kriya, Novartis, Ocular Therapeutix, OcuTerra, Oysterpoint, Prevent AI, REGENXBIO. Revana, Santen, Tenpoint, Vial, Cardinal, Coherus, 4DMT, Code C (Consultant/Contractor); Himanshu Banda Genentech, Code C (Consultant/Contractor); Mark Barakat Alcon, Alimera, Amgen, Asclepix, Aviceda, Bausch & Lomb, Clearside, Eyepoint, Genentech, Glaukos, Imprimis, Ingenia, Kriya, Novartis, Ocular Therapeutix, OcuTerra, Oysterpoint, Prevent AI, REGENXBIO. Revana, Santen, Tenpoint, Vial, Cardinal, Coherus, 4DMT, Code C (Consultant/Contractor), Clearside Biomedical, Eyepoint Pharmaceuticals, Kodiak Sciences, Genentech, Roche, Oxurion, REGENXBIO, Adverum Biotechnologies, Graybug, Annexon Biosciences, Gemini Therapeutics, Gyroscope Therapeutics, Ocular, Oculis, Opthea, ReNeuron, Stealth Biotherapeutics, Unity Biotechnology, Code F (Financial Support), NeuBase, Oxurion, RevOpsis Therapeutics , Code I (Personal Financial Interest); Ramanath Bhandari Novartis, Apellis, Regeneron, Vial, Code C (Consultant/Contractor), Kodiak Biosciences, REGENXBIO, Ionis, Regeneron, Code F (Financial Support), RevOpsis Therapeutics, Code I (Personal Financial Interest), RevOpsis Therapeutics, Code O (Owner), Glaucoma Drainage Device, RO-101, Code P (Patent); Emmanuel Chang None; Sara Haug None; Nikolas London Alimera, Genentech, Inc., Opthea, Amgen, Annexon, Apellis, Bayer, Gyroscope, Ionis, Kodiak Sciences, NGM Bio, Oxurion, Regenxbio, Regeneron, Sandoz, Code C (Consultant/Contractor), Genentech, Opthea, Annexon, Apellis, Gyroscope, Ionis, Kodiak Sciences, NGM Biopharmaceuticals, Oxurion, REGENXBIO, Regeneron, Code F (Financial Support); Veeral Sheth Genentech, Alimera, Novartis, Iveric Bio, Regeneron, Apellis, Code C (Consultant/Contractor), Genentech, Alimera, Novartis, Iveric Bio, Regeneron, Gyroscope, REGENXBIO, Chengdu Kanghong, NGM Biopharmaceuticals, SamChungDang, Sandoz, Alkahest, Apellis, Eyepoint, Oxurion, 4D Molecular Therapeutics, Ashvattha Therapeutics, Olix Pharmaceuticals, Janssen, OcuTerra , Code F (Financial Support); Jeremy Wolfe Allergan, Genentech, Regeneron, Code C (Consultant/Contractor), Allergan, Genentech, Novartis, Regeneron, Code F (Financial Support); Michael Singer Guidepoint, Aerie Pharmaceuticals, Novartis, Genentech, Allergan, Code C (Consultant/Contractor), Novartis, Genentech, Allergan, Optos, Allegro, Ionis, Aerpio, Apellis, Graybug Vision, Kodiak Biosciences, Code F (Financial Support); Carl Danzig Genentech, Roche, Regeneron, Bayer, Adverum, REGENXBIO, Allergan, Novartis, Iveric Bio, Code C (Consultant/Contractor), Genentech, Roche, Regeneron, Bayer, Adverum, Kodiak, Unity, REGENXBIO, Novartis, Iveric Bio, Alexion, Gyroscope, Code F (Financial Support); Arshad Khanani Abbvie, Adverum Biotechnologies, AGTC, Alimera Sciences, Allergan, Apellis Pharmaceuticals, Arrowhead, Pharmaceuticals, AsclepiX Therapeutics, Aviceda Therapeutics, Bausch & Lomb , BroadWing Bio, Cholgene Therapeutics, 4D Molecular Therapeutics, Eyepoint Pharmaceuticals, Fronterra Therapeutics, Gemini Pharmaceuticals, Genentech, Graybug Vision, Gyroscope Therapeutics, Iveric Bio, Janssen Pharmaceuticals, Kato Pharmaceuticals, Kartos Therapeutics, Kodiak Sciences, Kriya Therapeutics, Ocular Therapeutix, Oculis, Ocuterra, Opthea, Oxurion, Novartis, Perfuse, PolyPhotonix, Ray Therapeutics, Recens Medical, Regeneron Pharmaceuticals, REGENXBIO, Roche, Stealth Biotherapeutics Therapeutics, Thea Pharma, UNITY Biotechnology, Vanotech, Code C (Consultant/Contractor), Abbvie, Adverum Biotechnologies, Annexon Biosciences, Apellis Pharmaceuticals, AsclepiX Therapeutics, 4D Molecular Therapeutics, Gemini Pharmaceuticals, Genentech, Graybug Vision, Gyroscope Therapeutics, Iveric Bio, Janssen Pharmaceuticals, Kodiak, Neurotech, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Oculis, Ocuterra, Opthea, Oxurion, Recens Medical, REGENXBIO, Roche, UNITY Biotechnology, Aviceda Therapeutics, PolyPhotonix, Recens Medical, Code F (Financial Support)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2187. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Visual and Anatomic Outcomes in nAMD Patients with Subretinal Hemorrhage After Treatment with Faricimab in the TRUCKEE Study
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Hannah Khan, Aamir Abdul Aziz, Ashkan Michael Abbey, David RP Almeida, Robert L Avery, Himanshu K Banda, Mark Barakat, Ramanath Bhandari, Emmanuel Y Chang, Sara Haug, Nikolas J S London, Veeral Sheth, Jeremy Wolfe, Michael Andrew Singer, Carl J Danzig, Arshad M. Khanani; Visual and Anatomic Outcomes in nAMD Patients with Subretinal Hemorrhage After Treatment with Faricimab in the TRUCKEE Study. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2187.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose : Faricimab was recently approved by the FDA for neovascular age-related macular degeneration (nAMD). This multi-center, prospective study evaluates visual and anatomical improvements in nAMD patients with subretinal hemorrhages (SRH) following dual VEGF-A and Ang-2 inhibition with faricimab.

Methods : This multi-center, prospective study investigates nAMD patients with SRH following treatment with faricimab. Data collected includes demographics, treatment history, best corrected visual acuity (BCVA), central subfield thickness (CST), presence of SRH, presence and height of pigment epithelial detachment (PED), presence of subretinal/intraretinal fluid (SRF/IRF), and intraocular pressure (IOP). Snellen visual acuity was converted to Early Treatment Diabetic Retinopathy Study (ETDRS) scoring. SRH resolution and retinal fluid improvements are evaluated as a proportion of patients. Improvements in visual acuity, CST, and PED height are evaluated as averages. Safety is summarized.

Results : 17 eyes across 17 patients were recorded. The average age of 83.1 years and 70.5% of patients were female. Following one faricimab injection, 16 eyes saw a +3.45 letter (p=0.03034) mean increase, a -117.63mm (p=0.00118) mean decrease in CST, and resolution rates for SRH, SRF, and IRF of 11.8%, 60%, and 50%, respectively. Following three faricimab injections, 14 eyes demonstrated a +6.35 letter (p=0.13125) mean increase, mean CST decrease of -201.65mm (p=0.00298) and resolution rates for SRH, SRF, and IRF of 28.6%, 87.5%, and 66.7%, respectively. No adverse events have been reported.

Conclusions : NAMD patients with SRH have demonstrated favorable visual and anatomic outcomes following dual-inhibition treatment with faricimab, with acceptable safety compared to current agents. This study will continue to investigate safety and efficacy of faricimab in real-world nAMD patients with SRH. Latest data will be available at the time of presentation.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Attribution-NonCommercial-NoDerivatives
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept